Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAgrima MianRLRafaella LitvinKPKelsey Pandrangi

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows sequential bispecific antibody therapies yield 68% overall response in relapsed/refractory multiple myeloma, highlighting with common toxicities.

Key Points

  • To analyze the efficacy and toxicity of sequential bispecific antibody (BsAb) therapies in patients with relapsed/refractory multiple myeloma (RRMM).
  • Retrospective analysis of 31 patients with RRMM receiving two sequential BsAbs.
  • Data collected included treatment history, demographics, and response outcomes.
  • Kaplan-Meier methods were used to estimate progression-free survival (PFS) and overall survival (OS).
  • Overall response rate (ORR) for BsAb#1 was 68% with median progression-free survival (mPFS) of 162 days.
  • Median overall survival (OS) for BsAb#1 was 608 days; for BsAb#2 ORR was 55%.
  • Cytokine release syndrome occurred in 58% of patients, with neutropenia seen in 81% on BsAb#1.

Cite This Study

Mian et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e14chttps://doi.org/10.1182/blood-2025-6376
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients2025
  2. 2Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium2025
  3. 3Bispecific antibodies in the treatment of relapsed refractory multiple myeloma: A meta analysis.2026
  4. 4Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma2025 · 14 citations
  5. 5P56 | BASELINE IMMUNE PROFILE PREDICTS RESPONSE TO BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD MONOCENTRIC EXPLORATORY ANALYSIS2026